JAMAICA PROMOTIONS CORPORATION (JAMPRO) ANNOUNCES A MAJOR PHARMACEUTICAL PARTNERSHIP BETWEEN PURE JAMAICAN AND SWEDEN’S KLARIA PHARMA

THE PURE JAMAICAN GROUP OF COMPANIES AND KLARIA PHARMA WILL CONDUCT ACCELERATED R&D IN JAMAICA AND LAUNCH A NEW PHARMACEUTICAL DELIVERY SYSTEM FOR PSILOCYBIN, TO SUPPORT GLOBAL ADVANCEMENTS IN MENTAL HEALTH SCIENCE

July 14, 2021 – Montego Bay, Jamaica and Stockholm, Sweden – The Pure Jamaican Group of Companies (Pure Jamaican), including the pharmaceutical division Seven-10 based in Montego Bay, and Klaria Pharma Holding AB (Klaria), a Swedish pharmaceutical firm listed on NASDAQ First North (KLAR.ST), announced today that they have established an exclusive agreement to conduct R&D and to commercialize their offerings, across all of the LAC region (Latin America and Caribbean Region, which is defined as Mexico, Central America, South America and the Caribbean). The ground-breaking offering is a patented revolutionary, pharmaceutical, precision-dose delivery system for psilocybin to support global advancements in mental health science. 
 

For more information, please see the attached full Press Release.

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.